The IBEC-WCHSU study demonstrates that supramolecular nanoparticles can rapidly lower amyloid-β by 50-60% within one hour in transgenic mice engineered to overproduce the peptide, with behavioral rescue persisting six months post-treatment in animals aged to the human equivalent of 90. Unlike neuron-centric approaches, the intervention restores capillary integrity and pericyte function, reactivating endogenous clearance mechanisms rather than merely inhibiting plaque formation. This aligns with emerging vascular hypotheses of dementia, where blood-brain barrier leakage precedes cognitive symptoms by years, as shown in longitudinal human imaging cohorts. Prior coverage overlooked scalability challenges: nanoparticle biodistribution remains heterogeneous in larger brains, and off-target endothelial activation could exacerbate neuroinflammation in comorbid vascular disease. Synthesizing with a 2023 Neuron paper on pericyte loss in early Alzheimer's and a 2024 Lancet Neurology review of glymphatic impairment, the work suggests a feedback loop where restored vasculature sustains long-term Aβ efflux without continuous dosing. Limitations include small rodent cohorts typical of such models (often n<15 per arm), lack of wild-type controls for vascular specificity, and uncertain translation given species differences in barrier transport proteins. No preprint stage was involved; findings appeared directly in the peer-reviewed Signal Transduction and Targeted Therapy.